Showing results (241-250 of 345) with videos related to

Sort By:
Pageof 35
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 20, 2007
Incidence of antiheparin-platelet factor 4 antibodies and heparin-induced thrombocytopenia in Turkish patients undergoing cardiac surgeryMuzaffer Demir, Enver Duran, Omer Yigitbasi, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 5, 2003
Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom testRolandas Gerbutavicius, Omer Iqbal, Harry L Messmore, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|July 21, 2009
Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparinChristian Viskov, E Bouley, P Hubert, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|June 6, 2023
Comparison of the DOAC Dipstick Test on Urine Samples With Chromogenic Substrate Methods on Plasma Samples in Outpatients Treated With Direct Oral AnticoagulantsLoula Papageorgiou, Svetlana Hetjens, Jawed Fareed, et al.
Critical Care Medicine|July 23, 2020
Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated CoagulopathyMarcel Levi, Jean-Louis Vincent, Kosuke Tanaka, et al.
Molecular and Cellular Biochemistry|March 20, 2004
Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesisSarfraz Ahmad, Brian Untch, Sylvia Haas, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|January 19, 2022
Dysregulation of Biomarkers of Hemostatic Activation and Inflammatory Processes are Associated with Adverse Outcomes in Pulmonary EmbolismIman Darwish, Jawed Fareed, Yevgeniy Brailovsky, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|September 24, 2020
Protein C Pathway, Inflammation, and Pump Thrombosis in Patients With Left Ventricular Assist DevicesJeanine M Walenga, Tania A Torres, Walter P Jeske, et al.
Biochemical Pharmacology|April 25, 2009
Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparinsBoyangzi Li, Jiraporn Suwan, Jeffrey G Martin, et al.
Thrombosis Research|August 17, 2002
Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodiesBrian Untch, Sarfraz Ahmad, Harry L Messmore, et al.
Pageof 35